Clinical Trials Browser

OTHER × Triple Negative Breast Neoplasms × Moxifloxacin × Clear all

NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Phase 3 Recruiting

Triple Negative Breast Neoplasms